Dave Ricks has driven remarkable operational efficiency at Eli Lilly, reducing drug development timelines to 6.1 years while maintaining an $11B R&D budget, though this aggressive pace and scale creates potential sustainability concerns with 40+ countries awaiting product launches due to manufacturing constraints.